Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Qilian International Holding Group Limited (QLI)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.59000.0000 (0.00%)
At close: 03:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.5900
Open1.5601
Bid1.5200 x 1800
Ask1.6600 x 1100
Day's Range1.5200 - 1.6900
52 Week Range1.3600 - 4.9900
Volume9,164
Avg. Volume23,016
Market Cap56.843M
Beta (5Y Monthly)N/A
PE Ratio (TTM)17.67
EPS (TTM)0.0900
Earnings DateFeb 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-18% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for QLI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Qilian International Holding Gr
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 14,400 employees.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
Advertisement
Advertisement